New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
05:03 EDTSUPNSupernus announces positive Phase 2b results on SPN-810, advances to development
Supernus Pharmaceuticals received positive top-line results from its Phase 2b study on SPN-810 for the treatment of impulsive aggression in ADHD patients. The study is a multi-center randomized, double-blind, placebo controlled clinical trial in children 6-12 diagnosed with Attention Deficit and Hyperactivity Disorder, or ADHD, and characterized by impulsive aggression that is not controlled by optimal stimulant and psychosocial treatment. A total of 121 patients were randomized in the study across placebo and three doses of SPN-810. SPN-810 was well tolerated throughout the study across all doses. The two serious adverse events that occurred were not drug related. The company will be analyzing the full data-set in depth, and subsequently planning on meeting with the FDA to discuss next steps in the development program and the design and protocol for Phase III clinical trials.
News For SUPN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 10, 2014
07:35 EDTSUPNSupernus announces Paragraph IV ANDA filing for Oxtellar XR
Subscribe for More Information
December 9, 2014
07:36 EDTSUPNSupernus announces Paragraph IV ANDA filing for Trokendi XR
Subscribe for More Information
December 8, 2014
17:24 EDTSUPNOrchard Hill lowers stake in Supernus to 4.99% from 7.0%
Stake includes convertible notes.
December 4, 2014
06:09 EDTSUPNSupernus files $112.8M mixed securities shelf, 12.8M shares for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use